Description
CARIMUNE 6GM/CARIMUNE 12GM/PRIVIGEN 10GM VIALS
First action · last action
2018-02-01 · 2019-08-22
Transactions
3
First transaction's obligation
$493,127
Base + all options value (sum of deltas)
$552,774
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D50358
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2018-02-01+$493,127= $493,127
- Mod P000012018-09-27+$256,608= $749,735
- Mod P000022019-08-22-$196,961= $552,774
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2018-02-01 | +$493,127 | $493,127 | CARIMUNE 6GM/CARIMUNE 12GM/PRIVIGEN 10GM VIALS |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2018-09-27 | +$256,608 | $749,735 | CARIMUNE 6GM/CARIMUNE 12GM/PRIVIGEN 10GM VIALS |
| Mod P00002· CHANGE ORDER | 2019-08-22 | −$196,961 | $552,774 | CARIMUNE 6GM/CARIMUNE 12GM/PRIVIGEN 10GM VIALS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI H3WKVE9VBLY3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24826F0207 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $183,903 | FY2026 |
| 36C24826F0187 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $36,781 | FY2026 |
| 36C25226F0318 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $85,484 | FY2026 |
| 36C24826F0091 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $147,122 | FY2026 |
| 36C24826F0037 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $124,240 | FY2026 |
| 36C24824F0327 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $391,583 | FY2024 |
Other recipients under 6505 from 247-NETWORK CONTRACT OFFICE 7 (36C247) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24726P0690 | SINA DRUG LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $188,463 | FY2026 |
| 36C24726N0211 | BOSTON SCIENTIFIC CORP | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $248,982 | FY2026 |
| 36C24726F0100 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $228,396 | FY2026 |
| 36C24726F0053 | EXELAN PHARMACEUTICALS INC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $4,765,853 | FY2026 |
| 36C24726F0043 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $109,456 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24718F0668_3600_V797D50358_3600 · retrieved 2026-09-26.